Development of glucose-responsive 'smart' insulin systems

Current Opinion in Endocrinology, Diabetes, and Obesity
Nischay K RegeMichael A Weiss

Abstract

The complexity of modern insulin-based therapy for type I and type II diabetes mellitus and the risks associated with excursions in blood-glucose concentration (hyperglycemia and hypoglycemia) have motivated the development of 'smart insulin' technologies (glucose-responsive insulin, GRI). Such analogs or delivery systems are entities that provide insulin activity proportional to the glycemic state of the patient without external monitoring by the patient or healthcare provider. The present review describes the relevant historical background to modern GRI technologies and highlights three distinct approaches: coupling of continuous glucose monitoring (CGM) to deliver devices (algorithm-based 'closed-loop' systems), glucose-responsive polymer encapsulation of insulin, and molecular modification of insulin itself. Recent advances in GRI research utilizing each of the three approaches are illustrated; these include newly developed algorithms for CGM-based insulin delivery systems, glucose-sensitive modifications of existing clinical analogs, newly developed hypoxia-sensitive polymer matrices, and polymer-encapsulated, stem-cell-derived pancreatic β cells. Although GRI technologies have yet to be perfected, the recent advances acro...Continue Reading

References

Aug 1, 1979·European Journal of Immunology·A CoutinhoJ Andersson
Nov 19, 1968·Biochimica Et Biophysica Acta·H W RueliusF W Janssen
Jan 1, 1993·Annual Review of Cell Biology·K Drickamer, M E Taylor
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jan 1, 1996·Annual Review of Biochemistry·W I Weis, K Drickamer
Jul 1, 1997·Diabetes Care·W D LougheedB H Frank
Mar 24, 2000·Drugs·P S GilliesH M Lamb
Feb 19, 2002·Trends in Cell Biology·Alan R Saltiel, Jeffrey E Pessin
Mar 21, 2003·Medicinal Research Reviews·Wenqian YangBinghe Wang
May 27, 2003·Diabetes Care·Philip E CryerHarry Shamoon
Dec 20, 2003·Nature·Christopher M Dobson
Feb 13, 2004·The New England Journal of Medicine·R Paul Robertson
May 12, 2004·Organic & Biomolecular Chemistry·Malcolm P Nicholls, Prem K C Paul
Jan 7, 2005·Journal of Peptide Science : an Official Publication of the European Peptide Society·Thomas Hoeg-JensenJan Markussen
Mar 2, 2005·Diabetes Technology & Therapeutics·G M SteilK Rebrin
Sep 10, 2005·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·R H A BeckerH Scholtz
Feb 21, 2006·Biosensors & Bioelectronics·Ralph BallerstadtAshok Gowda
Feb 8, 2008·The New England Journal of Medicine·Mayank B Patel, Ashok Bhalla
Mar 12, 2008·The Journal of Biological Chemistry·Qing-xin HuaMichael A Weiss
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Sep 11, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Valérie RavaineBogdan Catargi
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators

❮ Previous
Next ❯

Citations

Jun 20, 2018·Diabetes Technology & Therapeutics·Timothy S BaileyJenine Y Stone
Jan 4, 2019·Advanced Healthcare Materials·Michael A VandenBerg, Matthew J Webber
Nov 7, 2019·Current Diabetes Reports·Simon H Friedman
Oct 1, 2019·American Journal of Therapeutics·Simona Cernea, Itamar Raz
Dec 27, 2019·American Journal of Therapeutics·Helena W Rodbard, David Rodbard
Nov 7, 2019·Current Drug Delivery·Sunil Kumar DubeyShailendra Saraf
Jan 4, 2020·Diabetologia·Amy S Shah, Kristen J Nadeau
Jun 21, 2019·Journal of Diabetes Science and Technology·Maria M DisotuarDanny Hung-Chieh Chou
Dec 25, 2017·Diabetologia·Jay S Skyler
Jun 28, 2018·Nature Reviews. Endocrinology·Martin Tauschmann, Roman Hovorka
Aug 10, 2019·Der Internist·M Ehren, H H Klein
Jan 7, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Andrej JanežLea Smircic-Duvnjak
Jan 24, 2021·Advanced Drug Delivery Reviews·Bhushan N KharbikarTejal A Desai
Mar 13, 2021·Diabetologia·Mark A JarosinskiMichael A Weiss
Nov 3, 2020·Molecular Metabolism·Thomas Hoeg-Jensen
Mar 16, 2021·American Journal of Physiology. Endocrinology and Metabolism·Ran ChengRémi Rabasa-Lhoret
Jul 30, 2020·Current Pharmaceutical Design·Xin WangHelong Quan
Jul 2, 2021·Pharmacological Reviews·Leslie S SatinEmily M Walker
Jan 6, 2022·Diabetes Care·Victor S HarrisonDavid M Harlan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.